Skip to main content

Search

Show all results for

Home

Person

Michael Groessl

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2026 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (22)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity

Paul Joseph Dyson, Ursula Röthlisberger, Wee Han Ang, Pablo Campomanes Ramos, Alexey Nazarov, Michael Groessl, Catherine Marie Amélie Clavel

Ruthenium compounds have become promising alternatives to platinum drugs by displaying specific activities against different cancers and favourable toxicity and clearance properties. Nonetheless, their molecular targeting and mechanism of action are poorly ...

Nature Research2014

Multinuclear Cytotoxic Metallodrugs: Synthesis and Biological Studies of Novel Bimetallic Titanium-Ruthenium and Gold Complexes

Alexey Nazarov, Angela Casini, Michael Groessl, Olivier Pierre Zava

Springer2014

Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs

Paul Joseph Dyson, Christian Hartinger, Angela Casini, Michael Groessl

Mass spectrometry (MS) has emerged as an important tool for studying anticancer metallodrugs in complex biological samples and for characterising their interactions with biomolecules and potential targets on a molecular level. The exact modes-of-action of ...

Royal Society of Chemistry2013